Tecnologia per a la monitorització i control de Diabetis

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Resumen de: WO2026148099A1

Techniques for improved respiratory therapy are provided. Glucose data of a user collected during a sleep session is accessed. Based at least in part on the glucose data, a plurality of transitions between sleep stages experienced by the user during the sleep session is determined. A sleep quality measure for the sleep session is generated based at least in part on the plurality of transitions. An apnea risk score for the user is generated based at least in part on the sleep quality measure, and one or more medical interventions for the user are provided based on the apnea risk score.

SYSTEM AND METHOD FOR TITRATING BASAL INSULIN DOSES

Resumen de: US20260192048A1

0000 A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Resumen de: WO2026148093A1

Techniques for improved respiratory therapy are provided. Glucose data of a user, collected while the user was awake, is accessed, where the user is a participant in a respiratory therapy. A metabolic health (MH) state of the user is determined based at least in part on the glucose data. A respiratory therapy configuration for a subsequent usage session of the user is generated based on evaluating the MH state using one or more MH models. A respiratory therapy flow generator of the user is instructed to implement the respiratory therapy configuration during a usage session.

SYSTEMS AND METHODS FOR USING CONTINUOUS KETONE MONITORING TO PROVIDE FITNESS OPTIMIZATION AND DISEASE DIAGNOSIS

Resumen de: WO2026147609A1

Certain aspects of the present disclosure provide a therapy management system configured to monitor analyte levels of a host during a time period using one or more analyte sensors to obtain analyte data, the analyte levels comprising at least glucose levels and ketone levels, and determine a metabolic fitness of the host based, at least in part, on the analyte data. The therapy management system is further configured to provide therapy management guidance to the host based, at least in part, on the determined metabolic fitness to improve the metabolic fitness of the host. The therapy management guidance includes at least one of a diet or meal recommendation for the host, an exercise recommendation for the host, or a lifestyle recommendation for the host.

MEDICAMENT DELIVERY SYSTEM USING LACTATE DATA

Resumen de: WO2026147654A1

A method of delivering a medicament to a subject for the treatment of diabetes includes: receiving glucose data and lactate data for the subject; adjusting medicament therapy to be delivered to the subject based at least in part on the glucose data and the lactate data; and delivering the adjusted medicament therapy to the subject.

A NEW SITE FOR TRANSPLANTATION

Resumen de: US20260191912A1

Methods for transplanting cells or tissues, in particular islets, into a sub-rectus sheath site. Methods for treating diabetes by transplanting islets, particularly hPSC-islets, into a sub-rectus sheath position. The sub-rectus sheath position is a new site for transplantation.

SYSTEM AND METHOD FOR DECISION SUPPORT USING LIFESTYLE FACTORS

Resumen de: US20260192043A1

0000 Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.

ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOF

Resumen de: AU2026204844A1

The present invention relates to variants of acid-alpha glucosidase and uses thereof. un u n

MITIGATION OF COMPRESSION EVENT FAILURE FOR CONTINUOUS GLUCOSE MONITORS

Resumen de: AU2024395288A1

Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.

Multi-State Engagement With Continuous Glucose Monitoring Systems

Resumen de: US20260191434A1

Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.

SYSTEMS, DEVICES, AND METHODS FOR MEAL INFORMATION COLLECTION, MEAL ASSESSMENT, AND ANALYTE DATA CORRELATION

Resumen de: US20260191433A1

Systems, devices, and methods for detecting, measuring and classifying meals for an individual based on analyte measurements. These results and related information can be presented to the individual to show the individual which meals are causing the most severe analyte response. These results can be organized and categorized based on preselected criteria or previous meals and results so as to organize and present the results in a format with reference to glucose as the monitored analyte. Various embodiments disclosed herein relate to methods, systems, and software applications intended to engage an individual by providing direct and timely feedback regarding the individual's meal-related glycemic response.

GLUCOSE LEVEL DEVIATION DETECTION

Resumen de: US20260191435A1

0000 Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

Growth factor substituents

Resumen de: GB2644972A

Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.

COMPOSITION FOR BASAL MEDIUM FOR ANIMAL CELL CULTURE

Resumen de: EP4772611A1

The present invention relates to a basal medium composition for animal cells. The basal medium composition for animal cells according to the present invention contains a yeast extract, amino acids, an inorganic salt, and a sugar, wherein the amino acids in the composition include cystine and/or cysteine, and glutamine.

SENSOR FOR DETECTING GLUCOSE AND LACTATE AND METHODS FOR DETERMINING AEROBIC AND ANAEROBIC THRESHOLDS

Resumen de: US2025169728A1

The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.

METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION

Resumen de: US20260184796A1

0000 Aspects of the present disclosure are directed to methods and compositions for facilitating β-cell regeneration by inhibition of the HIF1α-PFKFB3 pathway. Certain aspects describe methods for treatment and prevention of prediabetes and diabetes, including type 2 diabetes. Also disclosed are methods and compositions for enhancing β-cell regeneration.

VIRTUALLY MONITORING GLUCOSE LEVELS IN A PATIENT USING MACHINE LEARNING AND DIGITAL TWIN TECHNOLOGY

Resumen de: US20260182869A1

0000 A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's glucose level. The platform implements a short-term prediction model to generate a daily prediction of the patient's glucose level based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's glucose level during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's glucose level and updates a digital twin of the patient's metabolic profile.

METHODS, DEVICES, AND SYSTEMS FOR ADJUSTING LABORATORY HBA1C VALUES

Resumen de: US20260188443A1

0000 A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.

ENGINEERED STEM CELL DERIVED PANCREATIC BETA CELL COMPOSITIONS AND METHODS OF USE THEREOF

Resumen de: WO2026143067A1

The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.

COMPRESSION EVENT DETECTION FOR CONTINUOUS GLUCOSE MONITORS

Resumen de: AU2024389410A1

A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.

SYSTEMS AND METHODS FOR PROVIDING THERAPY MANAGEMENT GUIDANCE RELATED TO DIABETES FOR HEALTH IMPROVEMENT

Resumen de: WO2026142802A1

Certain aspects of the present disclosure provide a therapy management system configured to monitor at least glucose concentration levels of a patient during a first time period using one or more glucose sensors to obtain glucose data, and determine a diabetic state classification of the patient based on the glucose data. The diabetic state classification indicates a diabetic state of the patient and comprises one of: a healthy classification, a pre-diabetic classification, a mild type 2 diabetes (T2D) classification, a severe T2D classification, or a gestational diabetes classification. The therapy management system is further configured to provide personalized feedback to the patient based on the determined diabetic state classification, wherein the personalized feedback comprises a recommendation for at least one of an exercise session, a dietary change, a lifestyle modification, a medication adjustment, or a continuous glucose monitoring wear schedule.

MEDICAMENT UTILIZATION BASED THERAPY OPTIMIZATION

Resumen de: WO2026142937A1

In some embodiments, a method of automatically adjusting insulin therapy for a patient includes receiving, at a device associated with the patient, one or more glucose measurements generated by a continuous glucose monitoring (CGM) system of the patient for a period. The method also includes determining, at the device, basal insulin data and bolus insulin data of the patient for the period. The method also includes determining, at the device, a relationship between the basal insulin data and the bolus insulin data. The method also includes generating, at the device, an insulin therapy instruction for the patient based on the one or more glucose measurements and the determined relationship between the basal insulin data and the bolus insulin data, where the insulin therapy instruction includes a total bolus amount.

NON-INVASIVE GLUCOSE MEASUREMENT SYSTEM BASED ON BREATH AIR ANALYSIS

Resumen de: WO2026142537A1

Present invention relates to a needle-free glucose measurement system which enable measurement of blood glucose level using concentration value of N2O molecule available in breath air, which comprises an electronic assembly (1.1) which stabilizes the temperature and flow of wavelength-adjustable laser light source (1.2) and controls wavelength, a laser-based sensor (1) which determines concentration values of N2O molecule by measuring the adsorption amount of detector (1.5) wherein beams coming from laser light source (1.2) are adsorbed by N2O molecules in the breath air in the adsorption cell (1.4), and a processor (2) which determine glucose values in the blood using the concentration data coming from laser-based sensor (1).

Customized Alerts for Low Blood Glucose Levels

Resumen de: US20260182933A1

In accordance with some implementations, a method includes obtaining blood glucose (BG) data indicative of BG levels of an individual. The method includes obtaining a first sleepiness score associated with the individual. The method includes determining, based at least in part on the BG data, that a low blood sugar alert condition is satisfied. The method includes, in response to determining that the low blood sugar alert condition is satisfied, directing an alert subsystem to generate a first alert output based on the first sleepiness score.

BLOOD GLUCOSE AND BLOOD PRESSURE MEASUREMENT

Nº publicación: US20260182845A1 02/07/2026

Solicitante:

ACCURATE MEDITECH INC [TW]
Accurate Meditech Inc.

Resumen de: US20260182845A1

0000 A wearable device for measuring blood glucose and blood pressure for a user includes a main body including a first side and a second side formed on the opposite side of the first side; a first supporting frame protruding from the first side and a second supporting frame protruding from the second side; a belt portion having a first belt end detachably coupled to the first supporting frame, a second belt end detachably coupled to the second supporting frame, and at least one aligning mark, wherein the belt portion is positioned around a wrist of the user; wherein the main body includes at least one pressure sensor array assembly overlaid on a radial artery of the user; wherein the pressure sensor array assembly includes a plurality of apertures arranged one after another to form a cross-shaped pattern and at least four sensor elements arranged in a symmetrical configuration.